Achilles Other Operating Expenses vs Total Other Income Expense Net Analysis
| ACHL Stock | USD 1.02 0.01 0.99% |
Achilles Therapeutics financial indicator trend analysis is way more than just evaluating Achilles Therapeutics PLC prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Achilles Therapeutics PLC is a good investment. Please check the relationship between Achilles Therapeutics Other Operating Expenses and its Total Other Income Expense Net accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
Other Operating Expenses vs Total Other Income Expense Net
Other Operating Expenses vs Total Other Income Expense Net Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Achilles Therapeutics PLC Other Operating Expenses account and Total Other Income Expense Net. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Achilles Therapeutics' Other Operating Expenses and Total Other Income Expense Net is 0.97. Overlapping area represents the amount of variation of Other Operating Expenses that can explain the historical movement of Total Other Income Expense Net in the same time period over historical financial statements of Achilles Therapeutics PLC, assuming nothing else is changed. The correlation between historical values of Achilles Therapeutics' Other Operating Expenses and Total Other Income Expense Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Operating Expenses of Achilles Therapeutics PLC are associated (or correlated) with its Total Other Income Expense Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Other Income Expense Net has no effect on the direction of Other Operating Expenses i.e., Achilles Therapeutics' Other Operating Expenses and Total Other Income Expense Net go up and down completely randomly.
Correlation Coefficient | 0.97 |
| Relationship Direction | Positive |
| Relationship Strength | Very Strong |
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Achilles Therapeutics PLC. It is also known as Achilles Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Other Income Expense Net
Most indicators from Achilles Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Achilles Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. At this time, Achilles Therapeutics' Tax Provision is quite stable compared to the past year. Enterprise Value Over EBITDA is expected to rise to 1.36 this year, although the value of Issuance Of Capital Stock will most likely fall to 8,550.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 64.2M | 78.4M | 75.3M | 58.4M | Cost Of Revenue | 3.3M | 3.7M | 4.7M | 2.8M |
Achilles Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Achilles Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Achilles Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Current Liab | 681K | 1.4M | 1.3M | 8.6M | 13.5M | 14.1M | |
| Total Current Liabilities | 3.9M | 16.6M | 19.1M | 18.0M | 17.0M | 13.9M | |
| Net Tangible Assets | 101.3M | 189.2M | 289.5M | 197.0M | 226.6M | 173.7M | |
| Retained Earnings | (24.8M) | (58.0M) | (119.1M) | (190.3M) | (260.0M) | (247.0M) | |
| Accounts Payable | 902K | 6.3M | 3.7M | 5.2M | 5.6M | 4.0M | |
| Net Receivables | 4.5M | 7.3M | 11.2M | 16.0M | 10.4M | 9.5M | |
| Other Current Assets | 477K | 851K | 2.1M | 2.6M | 3.7M | 3.9M | |
| Other Stockholder Equity | 118.0M | 234.9M | 401.9M | 409.0M | 415.2M | 289.4M | |
| Total Current Assets | 103.1M | 187.8M | 284.7M | 196.6M | 145.6M | 170.7M | |
| Property Plant Equipment | 2.1M | 28.1M | 28.8M | 20.5M | 23.6M | 17.6M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.59) | Return On Assets (0.27) | Return On Equity (0.44) |
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.